Table 1

 Demographic, disease, patient questionnaire, and assessor questionnaire measures at screening by sequence group in patients randomised to receive celecoxib, acetaminophen or placebo in PACES 2 period, three treatment (six sequence) crossover clinical trials.

VariableCelecoxib-acetaminophen (n = 121)Acetaminophen-celecoxib (n = 114)Celecoxib-placebo (n = 60)Placebo-celecoxib (n = 115)Acetaminophen-placebo (n = 57)Placebo-acetaminophen (n = 57)p Value
Values are the mean (SE) unless stated otherwise.
VAS, visual analogue scale; GI, gastrointestinal.
A. PACES-a
Demographic measures
Age (years)63.4 (0.92)63.5 (0.94)65.5 (1.28)62.5 (0.96)63.7 (1.22)62.8 (1.30)0.583
Female (%)66.16451.762.659.668.40.445
Caucasian (%)90.186.088.388.786.084.20.848
⩽12 Years of education (%)50.048.244.842.961.850.00.329
Osteoarthritis measures
Duration of disease (years)8.4 (0.74)10.6 (0.80)10.7 (1.29)9.0 (0.85)8.5 (0.97)8.1 (1.09)0.093
Radiographic grade (0–4)2.77 (0.07)2.76 (0.06)2.67 (0.09)2.79 (0.06)2.75 (0.09)2.72 (0.10)0.916
Knee as index joint (%)85.787.582.781.478.582.10.529
% taking NSAID for OA68.672.866.767.073.775.40.318
WOMAC target joint (0–100)47.0 (1.91)51.6 (1.82)41.2 (2.30)45.6 (1.87)45.0 (2.81)45.9 (2.67)0.031
MDHAQ pain VAS (0–100)53.6 (1.72)56.5 (1.95)51.1 (2.47)55.1 (1.78)53.8 (2.79)54.6 (3.16)0.577
MDHAQ GI distress (0–100)12.8 (1.70)19.2 (2.29)13.5 (2.69)14.8 (1.81)10.9 (2.30)18.7 (3.57)0.074
(n = 127) (n = 123) (n = 62) (n = 119) (n = 62) (n = 63)
B. PACES-b
Demographic measures
Age (years)63.9 (0.89)63.4 (0.80)62.7 (1.28)62.8 (0.90)64.8 (1.31)63.4 (1.06)0.708
Female (%)66.163.471.071.462.957.10.410
Caucasian (%)86.683.779.090.883.985.70.350
⩽12 Years of education (%)46.445.553.244.451.650.80.822
Osteoarthritis measures
Duration of disease (years)10.5 (0.95)9.7 (0.75)8.2 (0.87)8.3 (0.75)10.4 (1.32)9.5 (1.10)0.589
Radiographic grade (0–4)2.81 (0.06)2.86 (0.07)2.84 (0.10)2.81 (0.07)2.94 (0.09)2.75 (0.10)0.782
Knee as index joint (%)85.180.590.383.282.284.20.405
% Taking NSAID for OA68.570.771.062.272.663.50.356
WOMAC target joint (0–100)46.3 (1.59)45.5 (1.84)47.2 (2.48)45.3 (1.87)45.4 (2.43)46.5 (2.43)0.997
MDHAQ pain VAS (0–100)55.0 (1.65)53.3 (1.97)53.8 (2.45)52.3 (1.89)53.6 (2.70)52.6 (2.38)0.945
MDHAQ GI distress (0–100)14.5 (1.72)17.5 (1.98)17.3 (3.27)14.4 (1.77)18.0 (2.99)18.7 (2.92)0.827